Parasol Med Tech, Inc. — SEC Form D Filing

Parasol Med Tech, Inc. filed an SEC Form D on September 10, 2026, reporting $2.37M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
September 10, 2026
Amount reported
$2.37M
Industry
Medical Devices
Website
https://www.parasolmedtech.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients with atrial fibrillation are at high risk of stroke due to blood clots forming in the heart's left atrial appendage. Existing prevention strategies, such as long-term blood thinners or current implantable closure devices, carry risks like bleeding, leaks, or device-related clots, leaving many patients underserved.

Solution

Parasol Medtech is developing a novel, patient-specific left atrial appendage closure device. This gel-based implant is designed to improve fit, sealing, and long-term safety, aiming to reduce complications, minimize leaks and clot formation, and decrease reliance on lifelong anticoagulation.

Why now

There is a growing prevalence of Atrial Fibrillation (AFib) affecting a significant portion of the adult population, and existing stroke prevention methods for AFib patients have critical safety and performance gaps, creating a market need for more effective solutions.

Verdict

This cleared because investors underwrote a clear, quantifiable improvement over existing, inadequate medical devices for a growing patient population, not because the underlying technology represented a fundamentally novel medical paradigm. The bet was on incremental clinical superiority and eventual acquisition by a larger MedTech player. The primary constraint on upside was the necessity of extensive, costly regulatory approvals and clinical trials, limiting rapid market penetration and requiring substantial follow-on capital before commercialization could meaningfully begin.

Source: SEC EDGAR Form D filing